Literature DB >> 21564524

Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success.

S A Lodhi1, K E Lamb, H U Meier-Kriesche.   

Abstract

Organ survival in the short-term period post-transplant has improved dramatically over the past few decades. Whether this has translated to a long-term survival benefit remains unclear. This study quantifies the progression of nonrenal solid organ transplant outcomes from 1989 to 2009 in liver, lung, heart, intestine and pancreas transplants. Long-term graft survival was analyzed using data on adult solid organ transplant recipients from the UNOS/SRTR database and is reported as organ half-life and yearly attrition rates. Liver, lung, heart, intestine and pancreas half-lives have improved from 5.8 to 8.5, 1.7 to 5.2, 8.8 to 11, 2.1 to 3.6 and 10.5 to 16.7 years, respectively. Long-term attrition rates have not shown the same consistent improvement, with the yearly attrition rate 5-10 years post-transplant for liver, lung, heart and pancreas changing from 4.7 to 4.3, 10.9 to 10.1, 6.4 to 5.1 and 3.3 to 4.2, respectively. Attrition rates for intestine and pancreas transplantation alone display more variability due to smaller sample size but exhibit similar trends of improved first-year attrition and relatively stagnant long-term attrition rates. With first-year survival and attrition rates almost at a pinnacle, further progress in long-term survival will come from targeting endpoints beyond first-year rejection and survival rates. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Mesh:

Year:  2011        PMID: 21564524     DOI: 10.1111/j.1600-6143.2011.03539.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  112 in total

Review 1.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

2.  Value of solid organ transplant-trained pharmacists in transplant infectious diseases.

Authors:  Jennifer Trofe-Clark; Tiffany Kaiser; Nicole Pilch; David Taber
Journal:  Curr Infect Dis Rep       Date:  2015-04       Impact factor: 3.725

3.  Below the waterline -- the danger of de novo donor-specific HLA antibodies.

Authors:  K E Kokko; R B Colvin
Journal:  Am J Transplant       Date:  2012-05       Impact factor: 8.086

4.  National Variation in Use of Immunosuppression for Kidney Transplantation: A Call for Evidence-Based Regimen Selection.

Authors:  D A Axelrod; A S Naik; M A Schnitzler; D L Segev; V R Dharnidharka; D C Brennan; S Bae; J Chen; A Massie; K L Lentine
Journal:  Am J Transplant       Date:  2016-03-31       Impact factor: 8.086

Review 5.  What's new in clinical solid organ transplantation by 2013.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-12-24

6.  CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection.

Authors:  Vyacheslav Palchevskiy; Ying Ying Xue; Rita Kern; Stephen S Weigt; Aric L Gregson; Sophie X Song; Michael C Fishbein; Cory M Hogaboam; David M Sayah; Joseph P Lynch; Michael P Keane; David G Brooks; John A Belperio
Journal:  JCI Insight       Date:  2019-05-14

Review 7.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

8.  Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients.

Authors:  R J Arasaratnam; I Tzannou; T Gray; P I Aguayo-Hiraldo; M Kuvalekar; S Naik; A Gaikwad; H Liu; T Miloh; J F Vera; R W Himes; F M Munoz; A M Leen
Journal:  Am J Transplant       Date:  2018-07-10       Impact factor: 8.086

9.  Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.

Authors:  Vikas R Dharnidharka; Mark A Schnitzler; Jiajing Chen; Daniel C Brennan; David Axelrod; Dorry L Segev; Kenneth B Schechtman; Jie Zheng; Krista L Lentine
Journal:  Transpl Int       Date:  2016-09-28       Impact factor: 3.782

10.  Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium.

Authors:  I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.